Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Abstract The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) progression/failure is unknown. Hence, we sought to examine real-world use and outcomes of lonca following CAR-T in patients with relapsed or refractory (R/R) diffuse large B-cell lymph...

Full description

Saved in:
Bibliographic Details
Main Authors: Narendranath Epperla, Melanie Lucero, Tom Bailey, Laura Mirams, Jolenta Cheung, Mona Amet, Gary Milligan, Lei Chen
Format: Article
Language:English
Published: Nature Publishing Group 2024-11-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-024-01195-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items